Carrying SNP rs17506395 (T > G) in TP63 gene and CCR5Δ32 mutation associated with the occurrence of breast cancer in Burkina Faso
Lassina Traoré, Mousso Savadogo, Abdou Azaque Zouré, Touwendpoulimdé Isabelle Kiendrebeogo, Fabienne Marie B. T. B. Soudre, Soayebo Dabre, Aida Djé Djénéba Traore, Marc Donald Wilfried Adico, Tilate Lare, Teega-Wendé Clarisse Ouedraogo, Rogomenoma Alice Ouedraogo, Abdoul Karim Ouattara, Edwige T. Yelemkoure, Alexis Yobi Sawadogo, Nayi Zongo, Hierrhum Aboubacar Bambara, Christelle W. Nadembega, Florencia W. Djigma, Jacques Simpore
AbstractGenetic alterations in the TP63 (GenBank: NC_000003.12, ID: 8626) and CCR5 (receptor 5 chemokine co-receptor) (GenBank: NC_000003.12, ID: 1234) genes may increase the risk of developing breast cancer. The aim of this study was to investigate the probable involvement of polymorphisms rs17506395 in the TP63 (tumour protein 63) gene and the CCR5Δ32 mutation in the occurrence of breast cancer in Burkina Faso. This case–control study included 72 patients and 72 controls. Genotyping of SNP rs17506395 (TP63) was performed by polymerase chain reaction–restriction fragment length polymorphism, and genotyping of the CCR5Δ32 mutation was performed by allele-specific oligonucleotide polymerase chain reaction. For SNP rs17506395 (TP63), the genotypic frequencies of wild-type homozygotes (TT) and heterozygotes (TG) were, respectively, 27.72 and 72.22% in cases and 36.11 and 63.89% in controls. No mutated homozygotes (GG) were observed. For the CCR5Δ32 mutation, the genotypic frequencies of wild-type homozygotes (WT/WT) and heterozygotes (WT/Δ32) were 87.5 and 13.5%, respectively, in the cases and 89.29 and 10.71%, respectively, in the controls. No mutated homozygotes (Δ32/Δ32) were observed. None of the polymorphisms rs17506395 of the TP63 gene (OR = 1.47, 95% CI = 0.69–3.17, P = 0.284) and the CCR5Δ32 mutation (OR = 1.32, 95% CI = 0.46–3.77; P = 0.79) were associated with the occurrence of breast cancer in this study.